Dr Michael John Festino, MD | |
42 North St, Saco, ME 04072-1903 | |
(207) 282-1559 | |
Not Available |
Full Name | Dr Michael John Festino |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Experience | 59 Years |
Location | 42 North St, Saco, Maine |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1124010111 | NPI | - | NPPES |
002159 | Other | ME | ANTHEM STAR ID |
104910000 | Medicaid | ME |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0000X | Internal Medicine - Cardiovascular Disease | 006038 (Maine) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Southern Maine Health Care | Biddeford, ME | Hospital |
Mailing Address | Practice Location Address |
---|---|
Dr Michael John Festino, MD 42 North St, Saco, ME 04072-1903 Ph: (207) 282-1559 | Dr Michael John Festino, MD 42 North St, Saco, ME 04072-1903 Ph: (207) 282-1559 |
News Archive
The Centers for Disease Control and Prevention (CDC) has released a report stating that the ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is on the rise among young adults and this rise is preventing the pandemic from abating.
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Sigmapharm Laboratories, LLC submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Hepsera® (adefovir dipivoxil).
Sorrento Therapeutics, Inc. ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the pricing of an underwritten public offering of 4,765,000 shares of common stock at a public offering price of $5.25 per share.
Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the year ended December 31, 2010.
› Verified 9 days ago
Dr. Richard G. Lemay, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 655 Main St, Southern Maine Va Outpatient Clinic, Saco, ME 04072 Phone: 207-294-3100 Fax: 207-286-3709 | |
Stephen A Sokol, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 655 Main St, Saco, ME 04072 Phone: 207-602-3571 Fax: 207-602-3573 | |
Donna M Stawasz, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 655 Main St, Saco Va Clinic, Saco, ME 04072 Phone: 207-623-8411 Fax: 207-286-3709 | |
Dr. William Stephen Gefvert, DO Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 655 Main St, Saco, ME 04072 Phone: 207-602-3571 Fax: 207-602-3573 | |
Robert Allen Ashley, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 655 Main St, Saco, ME 04072 Phone: 207-294-3100 |